Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Waldenstrom Macroglobulinemia × Lisaftoclax × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 3 Leukemia, Myeloid, Acute 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Neuroblastoma 1 Lymphoma, Mantle-Cell 1 Leukemia, Prolymphocytic, T-Cell 1 Leukemia 1 Hematologic Neoplasms 1 Dendritic Cell Sarcoma, Interdigitating 1 Breast Neoplasms 1 Amyloidosis 1

Interventions

Rituximab 99 Cyclophosphamide 63 fludarabine phosphate 55 Peripheral Blood Stem Cell Transplantation 52 Mycophenolic Acid 34 Whole-Body Irradiation 33 Bortezomib 33 ibrutinib 29 Dexamethasone 27 Tacrolimus 26 Cyclosporine 25 Busulfan 23 Etoposide 22 Melphalan 20 Filgrastim 20 zanubrutinib 18 Methotrexate 18 Lenalidomide 18 Antilymphocyte Serum 18 Radiotherapy 16 Bendamustine Hydrochloride 14 Sirolimus 13 Calcium Dobesilate 11 Flow Cytometry 10 Everolimus 10 ibritumomab tiuxetan 9 Prednisone 9 Indium 9 Cyclosporins 9 venetoclax 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04260217 2025-08-19

MAPLE-1

Ascentage Pharma Group Inc.

Phase 1 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡